Development of a Sensitive Assay to Screen Nanoparticles in vitro for Complement Activation.

ABSTRACT: Nanomedicines are often recognized by the innate immune system as a threat, leading to unwanted clearance due to complement activation. This adverse reaction not only alters the bioavailability of the therapeutic but can also cause cardiopulmonary complications and death in a portion of the population. There is a need for tools for assessing complement response in the early stage of development of nanomedicines. Currently, quantifying complement-mediated response in vitro is limited due to differences between in vitro and in vivo responses for the same precursors, differences in the complement systems in different species, and lack of highly sensitive tools for quantifying the changes. Hence, we have worked on developing complement assay conditions and sample preparati

SUBMITTER: Maisha N 

PROVIDER: S-EPMC7725268 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature